Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy (CAA) is a condition where amyloid protein builds up in the walls of the brain's blood vessels, which can lead to an increased risk of bleeding and strokes.
Cerebral Amyloid Angiopathy: New Treatment Approaches
We are studying whether non-invasive vagus nerve stimulation and low-sodium oxybate can help clear amyloid-beta from the brain in patients with cerebral amyloid angiopathy. This research aims to improve understanding of potential treatments for this condition.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 30 years old?
- Have you had 2 or fewer symptomatic intracerebral hemorrhages (ICH) in the past year?
- Are you currently pregnant or breastfeeding?
- Do you have a life expectancy of less than six months?
- Are you willing to limit your alcohol consumption to 1 unit per day and not later than 8 pm?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Academisch Ziekenhuis Leiden
Neurology
Leiden, Netherlands
Sponsor: Academisch Ziekenhuis Leiden
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.